Publications

CIBMTR>
Resources>
Publications

Researcher Reviews Publications

CIBMTR Publication List

Since 1972, using CIBMTR data and statistical resources has resulted in more than 1,800 publications.

CIBMTR also makes its publication analysis datasets freely available to the public for secondary analysis while safeguarding participants' privacy and protecting confidential and proprietary data.

View Publicly Available Datasets

Filter Results

Skip to Results Listing clear all

Keywords

Journal

Program/Committee

clear

Acute Leukemia(76)

Bioinformatics(157)

BIOSTATS(148)

BMT CTN(174)

Cellular Immunotherapy for Cancer (Phasing Out)(22)

Chronic Leukemia(46)

CIBMTR(168)

Coordinating Center(15)

Corporate Program(4)

Donor and Recipient Health Services(54)

Graft Sources and Manipulation(52)

Graft-versus-Host Disease(53)

Health Policy and Psychosocial Issues(14)

HSP/OPA(56)

IBMTR(209)

Immunobiology(173)

Infection and Immune Reconstitution(26)

International Studies(4)

Lymphoma(85)

Morbidity, Recovery and Survivorship(125)

NMDP(101)

Non-Malignant Diseases(58)

OTHER(12)

Pediatric Cancer(30)

Plasma Cell Disorders(60)

RCI BMT(10)

RETIRED - Health Services and International Studies(14)

Statistical Center(18)

See All

See Less

View Results

Browse Publications

Sort by:

Alphabetical
Sort Date "Newest First"
Sort Date "Oldest First"
Most Popular
Highest Rated
ePubDate Ascending
ePubDate Descending

Please wait while we gather your results.

Results Updated

20 Results Listed

Page 1 of 50
Next

Skip to Filters

2024 | Bone Marrow Transplantation

Role of the CIBMTR biorepository and registry in precision transplantation research.

Authors:

Guerrettaz RD, Spellman SR, Page KM

2024 | Clinical Transplantation

Novel scoring system for ranking hematopoietic stem cell transplantation.

Authors:

Baxter-Lowe LA, Wang T, Kuxhausen M, Spellman SR, Maiers M, Lee SJ, Saultz J, Arrieta-Bolaños E, Gadalla SG, Bolon Y, Betts BC

2024 | Bone Marrow Transplantation

Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia.

Authors:

Gui G, Ravindra N, Hegde PS, Andrew G, Mukherjee D, Wong ZC, Auletta JJ, El Chaer F, Chen EC, Chen Y, Corner A, Devine SM, Iyer SG, Jimenez Jimenez AM, De Lima MJG, Litzow MR, Kebriaei P, Saber W, Spellman SR, Zeger S, Page KM, Dillon LW, Hourigan CS

2024 | Journal of Clinical Oncology

Reply to: disparities in allograft access in the era of post-transplant cyclophosphamide-based mismatched unrelated donor transplantation.

Authors:

Shaffer BC, Gooptu M, DeFor T, Spellman SR, Stefanski HE, Shaw BE, Auletta JJ, Devine SM, Jimenez AM, Al Malki MM

2024 | Journal of Pediatric Hematology/Oncology

Why are higher cd34+ cell doses associated with improved outcomes among pediatric patients undergoing autologous hematopoietic stem cell transplant for central nervous system tumors - but not for high-risk neuroblastoma?

Authors:

Knight TE, Broglie L, Sharma A, Qayed M, Yanik GA

2024 | Journal of Hematology & Oncology

Prognostic impact of donor mitochondrial genomic variants in myelodysplastic neoplasms after stem-cell transplantation.

Authors:

Dong J, Arsang-Jang S, Zhang T, Chen Z, Bolon Y, Spellman SR, Urrutia R, Auer P, Saber W

2024 | Transplantation and Cellular Therapy

Representativeness of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) trial participants.

Authors:

Manmeet K, Horowitz MH, Mendizabal AM, Chen M, Foley A, Auletta JJ, Devine S, D'Souza A

2024 | Bone Marrow Transplantation

Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia.

Authors:

2024 | Bone Marrow Transplantation

Incidence of bacterial blood stream infections in patients with acute GVHD.

Authors:

Wallis W, Gulbis AM, Wang T, Wang T, Lee CJ, Sharma A, Williams KM, Nishihori T, Prestidge T, Gowda L, Byrne M, Krem MM, MacMillan ML, Kitko CL, Pidala J, Spellman SR, Lee SJ, Alousi AM

2024 | Bone Marrow Transplantation

Measurable residual FLT3 tyrosine kinase domain mutations before allogeneic transplant for acute myeloid leukemia.

Authors:

Hegde PS, Andrew G, Gui G, Ravindra N, Mukherjee D, Wong ZC, Auletta JJ, El Chaer F, Corner A, Devine SM, Jimenez-Jimenez AM, De Lima MJG, Litzow MR, Kebriaei P, Saber W, Spellman SR, Zeger SL, Page KM, Dillon LW, Hourigan CS

2024 | Blood Advances

Incremental eligibility criteria for the BMT CTN 1507 haploidentical trial for children with sickle cell disease.

Authors:

John TD, Walters MC, Rangarajan HG, Rahim MQ, McKinney CM, Bollard CM, Abusin G, Eapen M, Kassim AA, DeBaun MR

2024 | Blood Advances

Novel machine learning technique further clarifies unrelated donor selection to optimize transplantation outcomes.

Authors:

Spellman SR, Sparapani R, Maiers M, Shaw BE, Laud PW, Bupp C, He M, Devine SM, Logan BR

2024 | Communications Medicine

Multiple measures for self-identification improve matching donors with patients in unrelated hematopoietic stem cell transplant.

Authors:

Damotte V, Zhao C, Lin C, Williams E, Louzoun Y, Madbouly A, Kotlarz R, McDaniel M, Norman PJ, Wang Y, Maiers M, Hollenbach JA

2024 | Clinical Cancer Research

Correction: Randomized trial of a personalized dendritic cell vaccine after autologous stem cell transplant for multiple myeloma.

Authors:

Chung DJ, Shah N, Wu J, Logan B, Bisharat L, Callander N, Cheloni G, Anderson K, Chodon T, Dhakal B, Devine S, Somaiya Dutt P, Efebera Y, Geller N, Ghiasuddin H, Hematti P, Holmberg L, Howard A, Johnson B, Karagkouni D, Lazarus HM, Malek E, McCarthy P, McKenna D, Mendizabal A, Nooka A, Munshi N, O'Donnell L, Rapoport AP, Reese J, Rosenblatt J, Soiffer R, Stroopinsky D, Uhl L, Vlachos IS, Waller EK, Young JW, Pasquini MC, Avigan D

2024 | Frontiers in Genetics

Quantifying uncertainty of molecular mismatch introduced by mislabeled ancestry using haplotype-based HLA genotype imputation.

Authors:

Matern BM, Spierings E, Bandstra S, Madbouly A, Schaub S, Weimer ET, Nieman M

2024 | JAMA Network Open

Use of hematopoietic cell transplant for hematologic cancers by race, ethnicity, and age.

Authors:

Hahn T, Herr MM, Brazauskas R, Patel J, Ailawadhi S, Saber W, Khera N

2024 | Haematologica

Outcomes of patients with primary central nervous system lymphoma following CD19-targeted chimeric antigen receptor T-cell therapy.

Authors:

Mercadal S, Ahn KW, Allbee-Johnson M, Ganguly S, Ramakrishnan Geethakumari P, Hong S, Malone A, Murthy H, Pawarode A, Sica AR, Solh M, Ustun C, Shadman M, Sauter CS, Hamadani M, Herrera AF, Lee CJ

2024 | EClinicalMedicine

Long-term survival after unrelated donor marrow transplantation for aplastic anaemia after optimized conditioning regimen: A retrospective multicentre cohort study.

Authors:

Eapen M, Antin JH, Tolar J, Arai S, Horwitz ME, Kou J, Leifer E, McCarty JM, Nakamura R, Pulsipher MA, Rowley SD, Horowitz MH, Deeg HJ

2024 | EJHaem

Real-World treatment of large B-cell lymphoma with chimeric antigen receptor T-Cell therapy after loncastuximab tesirine.

Authors:

Hamadani M, Lucero M, DeVos JD, Chen L

2024 | The Lancet. Child & Adolescent Heal...

Late effects after allogeneic haematopoietic cell transplantation in children and adolescents with non-malignant disorders: a retrospective cohort study.

Authors:

Kahn J, Brazauskas R, Bo-Subait S, Buchbinder D, Hamilton BK, Schoemans H, Abraham AA, Agrawal V, Auletta JJ, Badawy SM, Beitinjaneh A, Bhatt NS, Broglie LA, Diaz M, Farhadfar N, Freytes CO, Gale RP, Ganguly S, Hayashi RJ, Hematti P, Hildebrandt GC, Inamoto Y, Kamble RT, Koo J, Lazarus HM, Mayo SJ, Mehta PA, Myers KC, Nishihori T, Prestidge T, Rotz SJ, Savani BN, Schears RM, Sharma A, Stenger E, Ustun C, Williams KM, Vrooman LM, Satwani P, Phelan R

Page 1 of 50
Next